Journal Scan

Metastasectomy for metastatic soft tissue sarcoma may be linked with longer survival

Posted on

Use of metastasectomy in addition to surgical management of the primary site has increased over the past 10 years in patients with metastatic soft tissue sarcoma of the extremity (STSE), according to a study.

This study included 1124 patients with initially metastatic STSE who received definitive surgical management of the primary site.

During the study period from 2004 to 2014, use of surgical management of the primary site plus metastasectomy increased (18.8% in 2004-2006; 33.3% in 2007-2009; and 47.9% in 2010-2014).

The 5-year overall survival was 30.8% when metastasectomy was added to surgical management of the primary site compared with 18.2% and 12.6% for patients treated with non-surgical adjuvant therapies and surgical management of the primary site alone.

In 24.1% of patients, there were positive surgical margins, which was associated with worse overall survival.

“These hypothesis-generating data warrant additional study,” the authors concluded.

Abugideiri M, Janopaul-Naylor J, Switchenko J, et al. Impact of metastasectomy and aggressive local therapy in newly diagnosed metastatic soft tissue sarcoma: An analysis of the NCDB. Ann Surg Oncol. 2021;doi: 10.1245/s10434-021-10466-4. Epub ahead of print. PMID: 34272614.